Drugs with Coverage Limitations and New Drug Review
Please Note:
- Date Review Completed and Conclusion columns are blank for those products currently undergoing review. Details will be updated as efficiently as possible following initial review.
- Conclusions are based upon decisions made at the time reviews are completed; historical information is not updated. Product management is subject to change based on new clinical evidence, provider/public feedback, advisory committee recommendations, financial considerations, etc.
- This contains approximately one year of New Drug details.
- Advisory Meeting Month is the month this recommendation will be presented at the quarterly Drug Prior Authorization Committee (DPAC) and Drug Utilization Review (DUR) Board meetings. For meeting dates, please see the MO HealthNet Calendar of Events. Certain agents may also be discussed at the quarterly Rare Disease Advisory Council meeting immediately prior to their presentation at their designated DPAC/DUR meeting.
For more information on this process please view the New Drug Review Process or contact the MO HealthNet Pharmacy Program at MHD.PharmacyAdmin@dss.mo.gov or call 573-751-6963.
| Trade Name | Generic Name | Date Review Began | Date Review Completed | Conclusion | Advisory Committee Month |
|---|---|---|---|---|---|
| AUSTEDO XR TITRATION KT(WK1-4) | DEUTETRABENAZINE | 07/19/2023 | 08/29/2023 | PDL Product | October 2023 |
| BRIXADI MONTH 96 MG/0.27ML SYR | BUPRENORPHINE | 07/19/2023 | 08/29/2023 | PDL Product | January 2024 |
| BRIXADI MONTH 32MG/0.64ML SYR | BUPRENORPHINE | 07/19/2023 | 08/29/2023 | PDL Product | January 2024 |
| VALSARTAN 4 MG/ML SOLUTION | VALSARTAN | 07/19/2023 | 08/29/2023 | PDL Product | October 2023 |
| BRIXADI MONTH 128MG/0.36ML SYR | BUPRENORPHINE | 07/19/2023 | 08/29/2023 | PDL Product | January 2024 |
| ADALIMUMAB-ADAZ(CF) 40 MG SYRG | ADALIMUMAB-ADAZ | 07/11/2023 | 08/22/2023 | PDL Product | January 2024 |
| LITFULO 50 MG CAPSULE | LITFULO 50 MG CAPSULE | 07/11/2023 | 08/22/2023 | PDL Product | January 2024 |
| HYRIMOZ(CF) PEN PSORIA 80-40MG | ADALIMUMAB-ADAZ | 07/11/2023 | 08/22/2023 | PDL Product | January 2024 |
| ADALIMUMAB-ADAZ(CF) PEN 40 MG | ADALIMUMAB-ADAZ | 07/11/2023 | 08/22/2023 | PDL Product | January 2024 |
| HADLIMA 40 MG/0.8 ML SYRINGE | ADALIMUMAB-BWWD | 07/11/2023 | 08/22/2023 | PDL Product | January 2024 |
| HYRIMOZ(CF) 10 MG/0.1 ML SYRNG | ADALIMUMAB-ADAZ | 07/11/2023 | 08/22/2023 | PDL Product | January 2024 |
| HADLIMA PUSHTOUCH 40 MG/0.8 ML | ADALIMUMAB-BWWD | 07/11/2023 | 08/22/2023 | PDL Product | January 2024 |
| HYRIMOZ(CF) 20 MG/0.2 ML SYRNG | ADALIMUMAB-ADAZ | 07/11/2023 | 08/22/2023 | PDL Product | January 2024 |
| SKYCLARYS 50 MG CAPSULE | OMAVELOXOLONE | 07/11/2023 | 08/22/2023 | Fiscal Edit | October 2023 |
| HADLIMA(CF) 40 MG/0.4 ML SYRNG | ADALIMUMAB-BWWD | 07/11/2023 | 08/22/2023 | PDL Product | January 2024 |